Online inquiry

IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6693MR)

This product GTTS-WQ6693MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLC34A2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001300868.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3177
UniProt ID Q14542
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6693MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11909MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ14942MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ11583MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ5400MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ10111MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ12661MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ2799MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-301
GTTS-WQ14694MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SCT-400
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW